Jiangbo Pharmaceuticals (JGBO) Inactive 10-K2009 FY Annual report

Filed: 28 Sep 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: AAA, abdominal, analytic, antipyretic, antitussive, appealing, arm, authoritative, Ban, Bird, bone, broker, buyback, calendar, capped, catalog, chose, Chronic, circumvention, Codification, cold, conferred, Couch, cough, CPI, CRDA, critical, delegated, difficulty, Dispersible, downgrade, driver, dysmenorrhoea, East, electuary, enrolled, excellent, exploit, exposure, fall, FAS, feasibility, feedback, FIE, finder, flat, format, frequent, fresh, Gan, Gao, Gen, granule, GSP, Gu, Haihe, headache, herb, herewith, Hongrui, hygiene, hypothetical, identical, immaterial, indepdendent, indirectly, inflation, inflationary, inspection, interviewing, JGBO, Jiang, Kang, Ke, labeling, Lan, literature, Mao, marrow, mentioned, metropolitan, mismatch, movement, Mu, NBS, NDRC, nonauthoritative, notified, oligminorrhea, orderly, pain, panel, pear, phlegm, Pian, portfolio, postpartum, prescription, provisional, reassessment, recall, recovery, refundable, regular, relieve, repatriate, repatriation, reputable, reputation, Road, satisfactory, seizure, Shangdon, shutdown, stay, stricter, substitute, Sui, surgery, syrup, Tang, taste, television, tendering, thin, thirteen, tier, TM, topical, unadjusted, undistributed, unobservable, Unofficial, usability, viral, wealthier, wife, winning, withdrawn, Yan, Yi, Zhi

Removed: amounting, APB, client, dismissal, dismissed, encouraged, exchanged, exit, FDA, goodwill, GTEC, initially, Los, manner, negotiating, proceeding, promissory, Rim

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

JGBO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 USC § 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Jiangbo Pharmaceuticals, Inc. (“the Company”) on Form 10-K for the period ended June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (“the Report”), I, Cao Wubo, Chief Executive Officer and President, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(a)

The annual report on Form 10-K for the year ended June 30, 2009 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)

Information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 28, 2009

/s/ Cao Wubo

Cao Wubo

Chief Executive Officer and President